[Treatment of chronic hepatitis C in patients coinfected with HIV: tolerability, drug interactions, therapeutic indications].
Service des Maladies Infectieuses et Tropicales, Hôpital Universitaire Raymond-Poincaré, Faculté de Médecine Paris-Ile-de-France-Ouest, Garches.
Christian
C
Perronne
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002986:Clinical Trials as Topic; D016049:Didanosine / Q000494:pharmacology / Q000627:therapeutic use; D004347:Drug Interactions; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy* / Q000821:virology; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D008019:Life Style; D008928:Mitochondria / Q000187:drug effects; D008991:Monitoring, Physiologic; D015337:Multicenter Studies as Topic; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D018119:Stavudine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D019562:Viral Load; D015215:Zidovudine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D019380:Anti-HIV Agents; D016898:Interferon-alpha; D018894:Reverse Transcriptase Inhibitors; D012254:Ribavirin; D015215:Zidovudine; D018119:Stavudine; D016049:Didanosine